Efficacy and Safety of Prostate Radiotherapy in Metastatic Castration-Sensitive Prostate Cancer
Study Overview
The PEACE-1 study investigated the effects of adding radiotherapy to standard treatments for men with newly diagnosed metastatic castration-sensitive prostate cancer. This study involved 77 hospitals across Europe and included 1173 male participants.
Key Findings
- Improved Survival: Adding radiotherapy to standard care with abiraterone significantly improved radiographic progression-free survival for patients with low-volume disease.
- No Overall Survival Benefit: Radiotherapy did not significantly affect overall survival rates in the same patient group.
- Safety Profile: The addition of radiotherapy did not increase the overall risk of severe side effects.
Practical Solutions and Value
Radiotherapy can be a valuable addition to standard care for patients with low-volume metastatic castration-sensitive prostate cancer, enhancing treatment outcomes without increasing toxicity. This approach could be integrated into standard treatment protocols for better patient management.
Support for Healthcare Providers
To streamline patient care, our AI-driven platform, DocSym, consolidates clinical guidelines and research into a single resource. This helps clinicians make informed decisions quickly.
Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, improving operational efficiency and patient outcomes while reducing paperwork.
Learn more about enhancing your clinic’s workflow and patient care at aidevmd.com.
